These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1956 related articles for article (PubMed ID: 34256172)
1. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172 [TBL] [Abstract][Full Text] [Related]
2. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy. Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446 [TBL] [Abstract][Full Text] [Related]
3. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection. Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA Clin Infect Dis; 2024 Jul; 79(1):86-95. PubMed ID: 38427848 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892 [TBL] [Abstract][Full Text] [Related]
6. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. Al-Ramahi JS; Shahzad M; Li K; DeJarnette S; Chaudhary SG; Lutfi F; Ahmed N; Balusu R; Bansal R; Abdelhakim H; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU Leuk Lymphoma; 2023 Dec; 64(12):1981-1991. PubMed ID: 37574842 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090 [TBL] [Abstract][Full Text] [Related]
8. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. Camargo JF; Mendoza MA; Lin R; Moroz IV; Anderson AD; Morris MI; Natori Y; Natori A; Raja M; Lekakis L; Beitinjaneh A; Jimenez A; Goodman M; Wang T; Komanduri KV; Pereira D Transpl Infect Dis; 2021 Aug; 23(4):e13625. PubMed ID: 33896088 [TBL] [Abstract][Full Text] [Related]
9. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721 [TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients. Hahn EH; Li H; Sauter CS; Mossad SB Transpl Infect Dis; 2024 Aug; 26(4):e14322. PubMed ID: 38937864 [TBL] [Abstract][Full Text] [Related]
12. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy. Kampouri E; Hill JA; Dioverti V Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14144. PubMed ID: 37767643 [TBL] [Abstract][Full Text] [Related]
14. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881 [TBL] [Abstract][Full Text] [Related]
15. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ Front Immunol; 2023; 14():1114131. PubMed ID: 36936918 [TBL] [Abstract][Full Text] [Related]
16. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554 [TBL] [Abstract][Full Text] [Related]
17. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. Lindsay J; Krantz EM; Morris J; Sweet A; Tverdek F; Joshi A; Yeh R; Hill JA; Greenwood M; Chen SC; Kong DCM; Slavin M; Pergam SA; Liu C Transplant Cell Ther; 2022 Aug; 28(8):511.e1-511.e10. PubMed ID: 35623614 [TBL] [Abstract][Full Text] [Related]
18. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients. Wu X; Wang L; Shen L; He L; Tang K J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Passweg JR; Baldomero H; Ciceri F; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; McLornan DP; Neven B; de Latour RP; Perić Z; Ruggeri A; Snowden JA; Sureda A Bone Marrow Transplant; 2023 Jun; 58(6):647-658. PubMed ID: 36879108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]